MedWatch

Vaccine disputes may harm pharmaceutical industry's reputation

Vaccine disagreements may risk breathing new life into the pharmaceutical industry skepticism of yonder years, according to MedWatch's sources.

Photo: Pedro Nunes/Reuters/Ritzau Scanpix

Recent conflicts between the EU and coronavirus vaccine-producing pharmaceutical companies can seriously harm the industry's reputation, according to ad company Mensch's partner, Frederik J. Preisler, and Communications Advisor Sune Bang.

News of broken agreements, fewer vaccines than promised and production problems can quickly breathe life into the kind of skepticism towards the pharmaceutical industry that used to be more predominant, according to the sources.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Latest news

See all jobs